Interim results for 4th quarter 2012

All time high for Navamedic

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced its 2012 results. Following a 24 per cent sales growth, Navamedic posted all time high sales of NOK 88.7 million.

"Navamedic's strong growth is due to the introduction of new products, volume growth for existing products and successful price increases. We have a substantial pipeline of new products ready for release in 2013 and expect a continued strong top line growth and improved profitability," said Navamedic CEO Olof Milveden.

Navamedic's group EBITDA improved from NOK -2.6 million in 2011 to 2.0 million last year. The Company's generic drugs business is still in a build-up phase and ended 2012 with an EBITDA of NOK -9.6 million, which is in line with the previous year's EBITDA. The Vitaflo business area ended 2012 with an EBITDA of NOK 11.6 million, compared to NOK 6.8 million the previous year. The Group's pre-tax profit for 2012 was NOK -5.0, an improvement from NOK -7.2 million in 2011.

For the fourth quarter alone, Navamedic saw a 29 per cent sales growth from the corresponding quarter in 2011 and booked sales of NOK 24.8 million. EBITDA for the quarter was NOK 0.9 million, up from NOK 0.3 million in the fourth quarter of 2011.

Navamedic continues its build-up in generic drugs and entered 2013 with several product launches and an expanded sourcing platform. Navamedic is cooperating with several leading manufacturers of generic drugs and aims at becoming a leading generics supplier in the Nordic and Benelux markets.

Navamedic is preparing a number of product launches in 2013 and predicts a continued strong sales growth. The Company targets a positive run rate by end 2013.

For further information, please call Olof Milveden, CEO, telephone +46 733463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

Navamedic ASA
Oslo, 14.02.2013

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.